2023
Chen, Jianan; Cheung, Helen M C; Karanicolas, Paul J; Coburn, Natalie G; Martel, Guillaume; Lee, Albert; Patel, Chirag; Milot, Laurent; Martel, Anne L
A radiomic biomarker for prognosis of resected colorectal cancer liver metastases generalizes across MRI contrast agents Journal Article
In: Frontiers in Oncology, vol. 13, pp. 898854, 2023, ISSN: 2234-943X.
Abstract | Links | BibTeX | Tags: colorectal cancer, contrast agents, liver, metastasis, MRI, radiomics
@article{Chen2023,
title = {A radiomic biomarker for prognosis of resected colorectal cancer liver metastases generalizes across MRI contrast agents},
author = {Jianan Chen and Helen M C Cheung and Paul J Karanicolas and Natalie G Coburn and Guillaume Martel and Albert Lee and Chirag Patel and Laurent Milot and Anne L Martel},
url = {http://www.ncbi.nlm.nih.gov/pubmed/36816920 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9932499 https://www.frontiersin.org/articles/10.3389/fonc.2023.898854/full},
doi = {10.3389/fonc.2023.898854},
issn = {2234-943X},
year = {2023},
date = {2023-02-01},
journal = {Frontiers in Oncology},
volume = {13},
pages = {898854},
abstract = {INTRODUCTION Contrast-enhanced MRI is routinely performed as part of preoperative work-up for patients with Colorectal Cancer Liver Metastases (CRLM). Radiomic biomarkers depicting the characteristics of CRLMs in MRI have been associated with overall survival (OS) of patients, but the reproducibility and clinical applicability of these biomarkers are limited due to the variations in MRI protocols between hospitals. METHODS In this work, we propose a generalizable radiomic model for predicting OS of CRLM patients who received preoperative chemotherapy and delayed-phase contrast enhanced (DPCE) MRIs prior to hepatic resection. This retrospective two-center study included three DPCE MRI cohorts (n=221) collected between January 2006 and December 2012. A 10-minute delayed Gd-DO3A-butrol enhanced MRI discovery cohort was used to select features based on robustness across contrast agents, correlation with OS and pairwise Pearson correlation, and to train a logistic regression model that predicts 3-year OS. RESULTS The model was evaluated on a 10-minute delayed Gd-DO3A-butrol enhanced MRI validation cohort (n=121), a 20-minute delayed Gd-EOB-DTPA (n=72) cohort from the same institute, and a 5-minute delayed Gd-DTPA cohort (n=28) from an independent institute. Two features were selected: minor axis length and dependence variance. The radiomic signature model stratified high-risk and low-risk CRLM groups in the Gd-DO3Abutrol (HR = 6.29},
keywords = {colorectal cancer, contrast agents, liver, metastasis, MRI, radiomics},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION Contrast-enhanced MRI is routinely performed as part of preoperative work-up for patients with Colorectal Cancer Liver Metastases (CRLM). Radiomic biomarkers depicting the characteristics of CRLMs in MRI have been associated with overall survival (OS) of patients, but the reproducibility and clinical applicability of these biomarkers are limited due to the variations in MRI protocols between hospitals. METHODS In this work, we propose a generalizable radiomic model for predicting OS of CRLM patients who received preoperative chemotherapy and delayed-phase contrast enhanced (DPCE) MRIs prior to hepatic resection. This retrospective two-center study included three DPCE MRI cohorts (n=221) collected between January 2006 and December 2012. A 10-minute delayed Gd-DO3A-butrol enhanced MRI discovery cohort was used to select features based on robustness across contrast agents, correlation with OS and pairwise Pearson correlation, and to train a logistic regression model that predicts 3-year OS. RESULTS The model was evaluated on a 10-minute delayed Gd-DO3A-butrol enhanced MRI validation cohort (n=121), a 20-minute delayed Gd-EOB-DTPA (n=72) cohort from the same institute, and a 5-minute delayed Gd-DTPA cohort (n=28) from an independent institute. Two features were selected: minor axis length and dependence variance. The radiomic signature model stratified high-risk and low-risk CRLM groups in the Gd-DO3Abutrol (HR = 6.29